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Signal transduction and metabolism cooperate to control cell fate, but mechanisms that link metabolic
substrates to functional decisions are elusive. Now, Chang et al. (2013) in Cell provide a mechanism whereby
available sugars dictate metabolic pathways in activated T cells and direct a nonmetabolic regulatory func-
tion of glyceraldehyde-3-phosphate dehydrogenase.A resurgence of interest in cellular meta-
bolism has emerged with the realization
that signaling pathways directly influence
metabolic reprogramming. In cancer,
oncogenic pathways directly promote a
metabolic program termed aerobic
glycolysis (glycolysis even in the presence
of abundant oxygen). Likewise, activation
of T cells to exit quiescence, proliferate,
and produce cytokines, such as interferon
g, also induces aerobic glycolysis. The
benefit of this form of metabolism has
been a point of debate since Otto
Warburg first described the phenomenon
in cancers in the 1920s. While inefficient
at generating ATP, consensus has
emerged that aerobic glycolysis acts to
provide biosynthetic building blocks and
support cell growth. Nevertheless, the
broad cellular physiological implications
of aerobic glycolysis for cell fate decisions
have been poorly understood. Now, in a
recent paper by Chang and colleagues
(2013), a link is established in activated
T cells between a glycolytic substrate
and a nonenzymatic function of a glyco-
lytic enzyme, influencing the functional
consequences of activation.
Several checkpoints now link the
availability of substrates, oxygen, or ATP
to signaling. For example, AMPK and
TORC1 ‘‘sense’’ ATP and amino acid
levels, respectively, and some metabolic
enzymes have been implicated in
signaling events, independent of their
metabolic functions. The question per-
sists, however, as to whether metabolic
enzymes can act as ‘‘sensors’’ of their
substrates to alter cell fate through
nonmetabolic processes (Wang and
Green, 2012). Chang and colleagues
(2013) describe such a convergence ofsignaling and metabolism in the function
of activated T lymphocytes: a metabolic
enzyme directly regulates the translation
of specific mRNAs in a manner controlled
by the availability of its substrate. There-
fore, the mode of energy production by
an activated T cell directly impacts on
the function of the cell, and we are begin-
ning to understand how.
To address the role of aerobic glycol-
ysis in the proliferation and signaling of
activated T cells, Chang et al. (2013)
modified the timing and capacity of
T cells to perform glycolysis or mitochon-
drial electron transport. They found that
electron transport becomes dispensable
in proliferating T lymphocytes, as rote-
none and antimycin A (complex I and III
inhibitors, respectively) did not prevent
cell-cycle progression once initiated.
This is in contrast to recent observations
showing that the function of complex III
is essential for T cell activation prior to
proliferation (Sena et al., 2013). Although
Chang et al. (2013) did not examine gluta-
mine utilization under these conditions, it
is possible that a-ketoglutarate (aKG) en-
ters the TCA cycle in reverse to directly
provide citrate as a source of lipid produc-
tion, as has been shown in activated
T cells under hypoxia. Chang et al.
(2013) went on to show by replacing
glucose with galactose that even aerobic
glycolysis is dispensable for proliferation
of activated T cells. Since the conversion
of galactose to glucose ‘‘costs’’ two
ATP, ATP cannot be gained by glycolysis
alone (Figure 1), making electron trans-
port essential for the energetic demands
of proliferation. Somewhat unexpectedly,
galactose carbons did not appear to enter
the glycolytic pathway in activated T cells,Cell Metaboand therefore the intermediary metabo-
lites of glycolysis presumably decline.
Rather, it is possible that galactose-
derived glucose is shuttled into the
pentose phosphate pathway for de novo
production of nucleotides (Figure 1).
But here is where things get particularly
interesting. While activated T cells grown
in galactose proliferated normally, their
ability to produce IFNg was severely
compromised. Levels of IFNg mRNA
were normal, but IFNg mRNA was not
found in polysomes of galactose-cultured
cells, and this was a function of a 30 AU-
rich element (ARE) in the IFNg mRNA
(Figure 1). The glycolytic enzyme glyceral-
dehyde-3-phosphate dehydrogenase
(GAPDH) had previously been found to
bind to this 30 ARE and inhibit the transla-
tion of IFNg, and indeed, the authors
found that GAPDH was bound under
galactose-fueled conditions. Remark-
ably, this binding and inhibition of IFNg
translation was blocked by the presence
of the GAPDH substrate, glyceralde-
hyde-3-phosphate (G3P), either provided
directly or by readdition of glucose. Pre-
sumably, G3P becomes limiting when
activated T cells are fueled with galactose
and GAPDH is released to block IFNg
translation and T cell function.
While GAPDH is generally considered a
metabolic enzyme (its ‘‘day job’’), it is
known to have other nonmetabolic activ-
ities (its ‘‘night jobs’’). GAPDH has previ-
ously been identified as a component of
the gamma interferon-activated inhibitor
of translation (GAIT) complex, which regu-
lates selective translation in myeloid cells
(Jia et al., 2012). While Chang et al. (2013)
did not find any evidence for the GAIT
complex in galactose-fueled T cells, G3Plism 18, July 2, 2013 ª2013 Elsevier Inc. 7
Figure 1. Glyceraldehyde-3-Phosphate Determines GAPDH
Suppression of IFNg Translation
Glucose and galactosewere found to differentially enter the glycolytic pathway
and regulate GAPDH. Galactose requires additional ATP to enter metabolic
pathways and did not appear to undergo glycolysis but rather enter the
pentose phosphate pathway (PPP). When G3P was limiting with galactose,
GAPDH associated with the 30 UTR of IFNgmRNA and prevented translation.
Increased glycolytic flux and G3P provided by glucose availability, however,
relieved GAPDH inhibition of IFNgmRNA translation. Thus, aerobic glycolysis
provides a nutrient signal through G3P to directly modify cytokine production.
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Previewsmay influence the activity of
this complex as well by con-
trolling the availability of
GAPDH. Other ‘‘night jobs’’
of GAPDH are also described,
including roles in promoting
(Hara et al., 2005) or inhibiting
(Colell et al., 2007) some
forms of cell death, regulation
of nuclear protein nitrosyla-
tion (Kornberg et al., 2010),
and possibly control of
autophagy/mitophagy (Colell
et al., 2007). Again, the
possible role for G3P in
controlling the availability of
GAPDH for these processes
remains to be tested.
Intriguingly, the activated,
galactose-fueled T cells ex-
pressed PD1, a marker of
T cell ‘‘exhaustion,’’ that
when ligated further inhibits
T cell function (Barber et al.,
2006). Whether G3P and
GAPDH control programmeddeath-1 (PD-1) expression is not known.
However, it may be important that
tumor-infiltrating T cells express PD-1,
and blockade of the PD-L1 (present on tu-
mors and inflamed tissues)-PD-1 interac-
tion enhances anticancer immunity
(Pardoll, 2012). Therefore, the metabolic
milieu of tumors (among other conditions)
may have a profound impact on T cell
biology and function, perhaps via this
GAPDH mechanism. If so, then develop-
ment of GAPDH agonists might have
promise for enhancing immunotherapies
through regulating the availability of
GAPDH for its night job activity in control-
ling transcription and, in turn, T cell
function.
Night jobs for other glycolytic enzymes
have been suggested for hexokinase-2
(Majewski et al., 2004) and PKM2 (Yang8 Cell Metabolism 18, July 2, 2013 ª2013 Elset al., 2011), and additional functions of
other metabolic enzymes may very well
emerge. The insights from Chang et al.
(2013) suggest that nutrients and sub-
strates in aerobic glycolysis not only sup-
port cell growth, but also may directly
modify cell signaling and other functional
aspects of cell physiology by influencing
nonmetabolic functions of metabolic
enzymes. The roles of specific substrates
(or products) should be examined,
possibly shedding new light on the
emerging connections between meta-
bolism, signal transduction, and cell fate.
We can envision the development of novel
substrate mimetics that stimulate or
inhibit the night jobs of GAPDH or other
metabolic enzymes to influence cell fate
decisions. Our emerging understanding
of the night jobs of some of these, suchevier Inc.as GAPDH, holds terrific
promise for integrating and
ultimately controlling the
connections between meta-
bolism and cell functions.
REFERENCES
Barber, D.L., Wherry, E.J., Maso-
pust, D., Zhu, B., Allison, J.P.,
Sharpe, A.H., Freeman, G.J., and
Ahmed, R. (2006). Nature 439,
682–687.
Chang, C.H., Curtis, J.D., Maggi,
L.B., Jr., Faubert, B., Villarino, A.V.,
O’Sullivan, D., Huang, S.C., van
der Windt, G.J., Blagih, J., Qiu, J.,
et al. (2013). Cell 153, 1239–1251.
Colell, A., Ricci, J.E., Tait, S.,
Milasta, S., Maurer, U., Bouchier-
Hayes, L., Fitzgerald, P., Guio-
Carrion, A., Waterhouse, N.J., Li,
C.W., et al. (2007). Cell 129,
983–997.
Hara, M.R., Agrawal, N., Kim, S.F.,
Cascio, M.B., Fujimuro, M., Ozeki,
Y., Takahashi, M., Cheah, J.H.,
Tankou, S.K., Hester, L.D., et al.
(2005). Nat. Cell Biol. 7, 665–674.Jia, J., Arif, A., Willard, B., Smith, J.D., Stuehr, D.J.,
Hazen, S.L., and Fox, P.L. (2012). Mol. Cell 47,
656–663.
Kornberg, M.D., Sen, N., Hara, M.R., Juluri, K.R.,
Nguyen, J.V., Snowman, A.M., Law, L., Hester,
L.D., and Snyder, S.H. (2010). Nat. Cell Biol. 12,
1094–1100.
Majewski, N., Nogueira, V., Bhaskar, P., Coy, P.E.,
Skeen, J.E., Gottlob, K., Chandel, N.S., Thomp-
son, C.B., Robey, R.B., and Hay, N. (2004). Mol.
Cell 16, 819–830.
Pardoll, D.M. (2012). Nat. Rev. Cancer 12,
252–264.
Sena, L.A., Li, S., Jairaman, A., Prakriya, M.,
Ezponda, T., Hildeman, D.A., Wang, C.R., Schu-
macker, P.T., Licht, J.D., Perlman, H., et al.
(2013). Immunity 38, 225–236.
Wang, R., and Green, D.R. (2012). Nat. Immunol.
13, 907–915.
Yang, W., Xia, Y., Ji, H., Zheng, Y., Liang, J.,
Huang, W., Gao, X., Aldape, K., and Lu, Z. (2011).
Nature 480, 118–122.
